These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 23877223)

  • 21. Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein.
    Scappini B; Gatto S; Onida F; Ricci C; Divoky V; Wierda WG; Andreeff M; Dong L; Hayes K; Verstovsek S; Kantarjian HM; Beran M
    Cancer; 2004 Apr; 100(7):1459-71. PubMed ID: 15042680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing the OCT4-PG1 pseudogene reduces OCT-4 protein levels and changes characteristics of the multidrug resistance phenotype in chronic myeloid leukemia.
    Lettnin AP; Wagner EF; Carrett-Dias M; Dos Santos Machado K; Werhli A; Cañedo AD; Trindade GS; de Souza Votto AP
    Mol Biol Rep; 2019 Apr; 46(2):1873-1884. PubMed ID: 30721421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glucosamine Reverses P-Glycoprotein-Mediated Multidrug Resistance in the Daunorubicin-Resistant Human Gastric Cancer Cells.
    Valinezhad Sani F; Mosaffa F; Jamialahmadi K; Palizban A
    Nutr Cancer; 2020; 72(3):522-527. PubMed ID: 31290701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines.
    Marques DS; Sandrini JZ; Boyle RT; Marins LF; Trindade GS
    Leuk Res; 2010 Jun; 34(6):757-62. PubMed ID: 19969351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multidrug resistance phenotype and its relation to stem cell characteristics in chronic myeloid leukemia.
    Lettnin AP; Wagner EF; Salgado MTSF; Cañedo AD; Rumjanek VM; Trindade GS; Votto APS
    Gene; 2024 Jan; 892():147848. PubMed ID: 37774806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LQB-118, a pterocarpanquinone structurally related to lapachol [2-hydroxy-3-(3-methyl-2-butenyl)-1,4-naphthoquinone]: a novel class of agent with high apoptotic effect in chronic myeloid leukemia cells.
    Maia RC; Vasconcelos FC; de Sá Bacelar T; Salustiano EJ; da Silva LF; Pereira DL; Moellman-Coelho A; Netto CD; da Silva AJ; Rumjanek VM; Costa PR
    Invest New Drugs; 2011 Dec; 29(6):1143-55. PubMed ID: 20499132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.
    Gromicho M; Dinis J; Magalhães M; Fernandes AR; Tavares P; Laires A; Rueff J; Rodrigues AS
    Leuk Lymphoma; 2011 Oct; 52(10):1980-90. PubMed ID: 21663515
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Grape seed proanthocyanidin extract reverses multidrug resistance in HL-60/ADR cells via inhibition of the PI3K/Akt signaling pathway.
    Lin KN; Jiang YL; Zhang SG; Huang SY; Li H
    Biomed Pharmacother; 2020 May; 125():109885. PubMed ID: 32007917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.
    Mahon FX; Belloc F; Lagarde V; Chollet C; Moreau-Gaudry F; Reiffers J; Goldman JM; Melo JV
    Blood; 2003 Mar; 101(6):2368-73. PubMed ID: 12609962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 7-Ketocholesterol overcomes drug resistance in chronic myeloid leukemia cell lines beyond MDR1 mechanism.
    Rosa Fernandes L; Stern AC; Cavaglieri RC; Nogueira FC; Domont G; Palmisano G; Bydlowski SP
    J Proteomics; 2017 Jan; 151():12-23. PubMed ID: 27343758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug resistance in cancer cells.
    Patel A; Tiwari AK; Chufan EE; Sodani K; Anreddy N; Singh S; Ambudkar SV; Stephani R; Chen ZS
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):189-99. PubMed ID: 23673445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line.
    Cheng J; Cheng L; Chen B; Xia G; Gao C; Song H; Bao W; Guo Q; Zhang H; Wang X
    Int J Nanomedicine; 2012; 7():2843-52. PubMed ID: 22745547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diverse cross-resistance phenotype to ET-743 and PM00104 in multi-drug resistant cell lines.
    Duan Z; Choy E; Jimeno JM; Cuevas Cdel M; Mankin HJ; Hornicek FJ
    Cancer Chemother Pharmacol; 2009 May; 63(6):1121-9. PubMed ID: 18828019
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
    Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
    J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reversal effect of arsenic sensitivity in human leukemia cell line K562 and K562/ADM using realgar transforming solution.
    Wang X; Zhang X; Xu Z; Wang Z; Yue X; Li H
    Biol Pharm Bull; 2013; 36(4):641-8. PubMed ID: 23358330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib is a substrate for various multidrug resistance proteins.
    Czyzewski K; Styczynski J
    Neoplasma; 2009; 56(3):202-7. PubMed ID: 19309222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug resistance modulators PSC 833 and CsA show differential capacity to induce apoptosis in lymphoid leukemia cell lines independently of their MDR phenotype.
    Lopes EC; Garcia M; Benavides F; Shen J; Conti CJ; Alvarez E; Hajos SE
    Leuk Res; 2003 May; 27(5):413-23. PubMed ID: 12620293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceritinib Enhances the Efficacy of Substrate Chemotherapeutic Agent in Human ABCB1-Overexpressing Leukemia Cells In Vitro, In Vivo and Ex-Vivo.
    Yang L; Li M; Wang F; Zhen C; Luo M; Fang X; Zhang H; Zhang J; Li Q; Fu L
    Cell Physiol Biochem; 2018; 46(6):2487-2499. PubMed ID: 29742496
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.